HBOT for Perianal Crohn's Disease
Key facts
- Who runs it
- Barts & The London NHS Trust
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 10 people, planned
- Starts
- 1 Jul 2027
- Expected to end
- 1 Jun 2028
- Type of study
- Interventional
- Treatments tested
- Hyperbaric Oxygen Therapy (HBOT)
- Record updated
- 13 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Aged 18 years or older. Confirmed diagnosis of Crohn's disease. Presence of at least one draining perianal fistula of cryptoglandular origin secondary to Crohn's disease; Refractory perianal fistulising disease despite conventional and/or advanced medical therapy, as determined by the treating clinician; Stable Crohn's disease medical therapy for at least 4 weeks prior to enrolment. Able and willing to undergo hyperbaric oxygen therapy. Able to provide written informed consent
Who cannot take part
- Severe claustrophobia not manageable within the hyperbaric chamber. Pregnancy or breastfeeding. Active malignancy requiring treatment. Requirement for major surgery during the HBOT treatment period. Inability to comply with the study procedures or complete the HBOT treatment course
- Any medical condition that, in the opinion of the investigator, would make participation unsafe or interfere with study assessments
- Age <18 years. Inability or unwillingness to provide informed consent. Contraindication to hyperbaric oxygen therapy, including untreated pneumothorax
- -
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Background Perianal fistulae are among the most disabling complications of Crohn's disease, causing significant morbidity, impaired quality of life, and substantial healthcare utilisation. Despite advances in biologic and surgical therapies, many patients experience persistent fistula drainage and fail to achieve durable healing.
Read full original descriptionShow less
Tissue hypoxia is a key regulator of intestinal inflammation and impaired wound healing in inflammatory bowel disease. Hyperbaric oxygen therapy (HBOT) increases tissue oxygenation, promotes angiogenesis, modulates inflammatory pathways, and may enhance fistula healing.
Preliminary studies suggest that HBOT is a safe and effective adjunctive treatment for refractory perianal Crohn's fistulae, with reported clinical response rates of 75-87% and remission rates of 50-60%. However, current evidence is limited by small sample sizes and the absence of prospective studies within UK clinical practice.
Aim To evaluate the preliminary efficacy of HBOT in patients with refractory perianal Crohn's fistulae treated in an outpatient setting.
Methods This prospective pilot study will recruit ten adults with refractory perianal Crohn's fistulae from the Inflammatory Bowel Disease service at Barts Health NHS Trust. Refractory disease will be defined as persistent fistula drainage or failure to heal despite optimised medical therapy and appropriate surgical management. Participants will undergo HBOT 100% oxygen at 2.4 ATA for approximately 90 minutes per session, 40 sessions over 8 weeks. The primary outcome will be overall clinical response, defined as either clinical remission (complete cessation of fistula drainage) or partial response (clinically meaningful reduction in drainage and symptoms). Secondary outcomes will include treatment adherence, safety, tolerability, patient acceptability, and feasibility of recruitment and study completion.
Expected Impact This pilot study will generate preliminary efficacy and feasibility data to inform the design, outcome measures, and sample size calculations of a larger clinical trial evaluating HBOT as a novel treatment strategy for refractory perianal Crohn's disease in the United Kingdom.
The group in the trial
- HBOT Treatment ArmTreatment being tested
Single experimental arm including patients with refractory Crohn's disease fistulae. Patients will receive hyperbaric oxygen therapy (HBOT) in addition to standard medical care. HBOT consists of 40 treatment sessions delivered over approximately 8 weeks, with participants breathing 100% oxygen at 2.4 atmospheres absolute (ATA) for approximately 90 minutes per session in a multiplace hyperbaric chamber
Treatment: Hyperbaric Oxygen Therapy (HBOT)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Hyperbaric Oxygen Therapy (HBOT) for Refractory Crohn's Perianal Fistulae: a Prospective Interventional Pilot Study
- Record updated
- 13 November 2026